These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 51006)

  • 21. [Pyocin typization of Pseudomonas aeruginosa].
    Vlajinac H
    Srp Arh Celok Lek; 1974 Dec; 102(12):901-11. PubMed ID: 4219453
    [No Abstract]   [Full Text] [Related]  

  • 22. [Serotyping and pyocin typing of Pseudomonas aeruginosa in a study of intrahospital infections].
    Tomanović B; Joković B; Tatić M; Mirović V; Nanusević O
    Vojnosanit Pregl; 1991; 48(1):31-3. PubMed ID: 1905081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.
    Young LS
    J Infect Dis; 1972 Sep; 126(3):277-87. PubMed ID: 4626510
    [No Abstract]   [Full Text] [Related]  

  • 24. [Appearance of various pyocin types and subtypes of Pseudomonas aeruginosa in the same patient].
    Vlajinac H
    Vojnosanit Pregl; 1978; 35(4):269-72. PubMed ID: 100965
    [No Abstract]   [Full Text] [Related]  

  • 25. Novel bacteriocins with predicted tRNase and pore-forming activities in Pseudomonas aeruginosa PAO1.
    Parret A; De Mot R
    Mol Microbiol; 2000 Jan; 35(2):472-3. PubMed ID: 10652108
    [No Abstract]   [Full Text] [Related]  

  • 26. Epidemiological markers for Pseudomonas aeruginosa. 1. Serogrouping, pyocine typing--and their interrelations.
    Bergan T
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1973 Feb; 81(1):70-80. PubMed ID: 4199590
    [No Abstract]   [Full Text] [Related]  

  • 27. Purification and characterization of pyocins R from Pseudomonas aeruginosa.
    al-Rubiee R; al-Mudaffar S; Hassan F; al-Ani F
    Folia Microbiol (Praha); 1988; 33(6):520-4. PubMed ID: 3149253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
    Mates A; Zand P
    J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotyping and pyocin typing of Pseudomonas aeruginosa from clinical specimens.
    Kurup VP; Sheth NK
    Am J Clin Pathol; 1976 Apr; 65(4):557-63. PubMed ID: 817593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Electronic microscopy of pyocines of Ps. aeruginosa (author's transl)].
    García Quintana H; Hernández A; Asenjo S; Polette M
    Rev Med Chil; 1979 Jun; 107(6):479-85. PubMed ID: 120965
    [No Abstract]   [Full Text] [Related]  

  • 31. Bacteriocin-mediated competition in cystic fibrosis lung infections.
    Ghoul M; West SA; Johansen HK; Molin S; Harrison OB; Maiden MC; Jelsbak L; Bruce JB; Griffin AS
    Proc Biol Sci; 2015 Sep; 282(1814):. PubMed ID: 26311664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pyocine typing of Pseudomonas aeruginosa: association between antigenic structure and pyocine type.
    Csiszár K; Lányi B
    Acta Microbiol Acad Sci Hung; 1970; 17(4):361-70. PubMed ID: 4998385
    [No Abstract]   [Full Text] [Related]  

  • 33. [Extraction and characteristics of agglutinating sera to the O-antigens of Pseudomonas aeruginosa].
    Smirnova NE; Akatova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Mar; 0(3):119-22. PubMed ID: 804787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and functional analysis of a bacteriocin, pyocin S6, with ribonuclease activity from a Pseudomonas aeruginosa cystic fibrosis clinical isolate.
    Dingemans J; Ghequire MG; Craggs M; De Mot R; Cornelis P
    Microbiologyopen; 2016 Jun; 5(3):413-23. PubMed ID: 26860427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. R-type pyocin is required for competitive growth advantage between Pseudomonas aeruginosa strains.
    Heo YJ; Chung IY; Choi KB; Cho YH
    J Microbiol Biotechnol; 2007 Jan; 17(1):180-5. PubMed ID: 18051371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defective pyocin particles produced by some mutant strains of Pseudomonas aeruginosa.
    Shinomiya T; Osumi M; Kageyama M
    J Bacteriol; 1975 Dec; 124(3):1508-21. PubMed ID: 811648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pyocine types of Pseudomonas aeruginosa strains isolated from patients in Diyarbakir (author's transl)].
    Yumul C
    Mikrobiyol Bul; 1980 Apr; 14(2):109-15. PubMed ID: 6780769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of FiuA Outer Membrane Receptor Polymorphism on the Resistance of
    Latino L; Patin D; Chérier D; Touzé T; Pourcel C; Barreteau H; Mengin-Lecreulx D
    J Bacteriol; 2019 Jul; 201(13):. PubMed ID: 30988031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Four new pyocine types of "Pseudomonas aeruginosa": epidemiological significance (author's transl)].
    Santos-Ferreira MO; Vieu JF
    Ann Microbiol (Paris); 1977; 128B(4):487-94. PubMed ID: 416740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A predicted immunity protein confers resistance to pyocin S5 in a sensitive strain of Pseudomonas aeruginosa.
    Rasouliha BH; Ling H; Ho CL; Chang MW
    Chembiochem; 2013 Dec; 14(18):2444-6. PubMed ID: 24222552
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.